{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:23:45Z","timestamp":1772277825159,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s10072-024-07496-7","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:02:12Z","timestamp":1712034132000},"page":"4451-4462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial"],"prefix":"10.1007","volume":"45","author":[{"given":"Chananchida","family":"Sirilertmekasakul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akkanat","family":"Panto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pattanan","family":"Lekhalawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pariyada","family":"Panyarachun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Porpim","family":"Jindasakchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-9699","authenticated-orcid":false,"given":"Wanakorn","family":"Rattanawong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"issue":"19","key":"7496_CR1","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Engl J Med 383(19):1866\u20131876","journal-title":"N Engl J Med"},{"issue":"10283","key":"7496_CR2","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Terwindt GM, Al-Karagholi MA, de Boer I, Lee MJ, Hay DL et al (2021) Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397(10283):1496\u20131504","journal-title":"Lancet"},{"key":"7496_CR3","doi-asserted-by":"publisher","unstructured":"GBD 2016 Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the global burden of disease study 2016 [published correction appears in Lancet Neurol. 2021 Dec;20(12):e7]. Lancet Neurol 17(11):954\u2013976. https:\/\/doi.org\/10.1016\/S1474-4422(18)30322-3","DOI":"10.1016\/S1474-4422(18)30322-3"},{"issue":"1","key":"7496_CR4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21(1):137","journal-title":"J Headache Pain"},{"issue":"6","key":"7496_CR5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1468-2982.2004.00691.x","volume":"24","author":"ME Bigal","year":"2004","unstructured":"Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB (2004) Transformed migraine and medication overuse in a tertiary headache centre\u2013clinical characteristics and treatment outcomes. Cephalalgia 24(6):483\u2013490","journal-title":"Cephalalgia"},{"issue":"7","key":"7496_CR6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1046\/j.1526-4610.2001.041007638.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF (2001) Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 41(7):638\u2013645","journal-title":"Headache"},{"issue":"1","key":"7496_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1\u2013211","journal-title":"Cephalalgia"},{"issue":"10","key":"7496_CR8","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1111\/head.12201","volume":"53","author":"RB Lipton","year":"2013","unstructured":"Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML (2013) Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 53(10):1548\u20131563","journal-title":"Headache"},{"key":"7496_CR9","volume":"12","author":"W Rattanawong","year":"2022","unstructured":"Rattanawong W, Rapoport A, Srikiatkhachorn A (2022) Neurobiology of migraine progression. Neurobiol. Pain 12:100094","journal-title":"Pain"},{"issue":"1","key":"7496_CR10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s10194-020-01111-8","volume":"21","author":"M Torres-Ferr\u00fas","year":"2020","unstructured":"Torres-Ferr\u00fas M, Ursitti F, Alpuente A, Brunello F, Chiappino D, de Vries T et al (2020) From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain 21(1):42","journal-title":"J Headache Pain"},{"issue":"5","key":"7496_CR11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40263-021-00818-9","volume":"35","author":"C Sun-Edelstein","year":"2021","unstructured":"Sun-Edelstein C, Rapoport AM, Rattanawong W, Srikiatkhachorn A (2021) The evolution of medication overuse headache: history, pathophysiology and clinical update. CNS Drugs 35(5):545\u2013565","journal-title":"CNS Drugs"},{"issue":"1","key":"7496_CR12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","volume":"20","author":"M Leonardi","year":"2019","unstructured":"Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life. J Headache Pain 20(1):41","journal-title":"J Headache Pain"},{"issue":"7","key":"7496_CR13","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/head.14527","volume":"63","author":"Z Ahmed","year":"2023","unstructured":"Ahmed Z, Honomichl R, Thompson SF, Cohen JM, Schuster A, Thompson NR et al (2023) Clinical characteristics and patient-reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: a retrospective observational study. Headache 63(7):908\u2013916","journal-title":"Headache"},{"issue":"1","key":"7496_CR14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","volume":"9","author":"S Ashina","year":"2023","unstructured":"Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C et al (2023) Medication overuse headache. Nat Rev Dis Primers 9(1):5","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"7496_CR15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamaneurol.2020.1179","volume":"77","author":"LN Carlsen","year":"2020","unstructured":"Carlsen LN, Munksgaard SB, Nielsen M, Engelstoft IMS, Westergaard ML, Bendtsen L et al (2020) Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. JAMA Neurol 77(9):1069\u20131078","journal-title":"JAMA Neurol"},{"issue":"7","key":"7496_CR16","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/ene.14268","volume":"27","author":"HC Diener","year":"2020","unstructured":"Diener HC, Antonaci F, Braschinsky M, Evers S, Jensen R, Lainez M et al (2020) European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol 27(7):1102\u20131116","journal-title":"Eur J Neurol"},{"issue":"1","key":"7496_CR17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s42466-022-00200-0","volume":"4","author":"HC Diener","year":"2022","unstructured":"Diener HC, Kropp P, Dresler T, Evers S, F\u00f6rderreuther S, Gaul C et al (2022) Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline. Neurol Res Pract 4(1):37","journal-title":"Neurol Res Pract"},{"issue":"7","key":"7496_CR18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/ene.13318","volume":"24","author":"ES Kristoffersen","year":"2017","unstructured":"Kristoffersen ES, Straand J, Russell MB, Lundqvist C (2017) Lasting improvement of medication-overuse headache after brief intervention - a long-term follow-up in primary care. Eur J Neurol 24(7):883\u2013891","journal-title":"Eur J Neurol"},{"issue":"5","key":"7496_CR19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/jnnp-2014-308548","volume":"86","author":"ES Kristoffersen","year":"2015","unstructured":"Kristoffersen ES, Straand J, Vetvik KG, Benth J, Russell MB, Lundqvist C (2015) Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial. J Neurol Neurosurg Psychiatr. 86(5):505\u201312","journal-title":"J Neurol Neurosurg Psychiatr."},{"issue":"1","key":"7496_CR20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","volume":"22","author":"E Caronna","year":"2021","unstructured":"Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (2021) Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain 22(1):120","journal-title":"J Headache Pain"},{"key":"7496_CR21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jclinepi.2021.09.021","volume":"141","author":"S Minozzi","year":"2022","unstructured":"Minozzi S, Dwan K, Borrelli F, Filippini G (2022) Reliability of the revised Cochrane risk-of-bias tool for randomised trials (RoB2) improved with the use of implementation instruction. J Clin Epidemiol 141:99\u2013105","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"7496_CR22","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/head.14206","volume":"61","author":"MJ Marmura","year":"2021","unstructured":"Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ et al (2021) Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. Headache 61(9):1421\u20131431","journal-title":"Headache"},{"issue":"1","key":"7496_CR23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","volume":"21","author":"SD Silberstein","year":"2020","unstructured":"Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21(1):114","journal-title":"J Headache Pain"},{"issue":"3","key":"7496_CR24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/0333102420966658","volume":"41","author":"DW Dodick","year":"2021","unstructured":"Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J et al (2021) Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 41(3):340\u2013352","journal-title":"Cephalalgia"},{"issue":"20","key":"7496_CR25","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U et al (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92(20):e2309\u2013e2320","journal-title":"Neurology"},{"issue":"6","key":"7496_CR26","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s40120-023-00531-3","volume":"12","author":"N Imai","year":"2023","unstructured":"Imai N, Isogai Y, Shibasaki Y, Nakai M, Ishida M, Ning X et al (2023) Effects of fremanezumab on medication overuse in Japanese chronic migraine patients: post hoc analysis of a multicenter, randomized, double-blind, placebo-controlled trial. Neurol Ther 12(6):1981\u20131991","journal-title":"Neurol Ther"},{"issue":"3","key":"7496_CR27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254","journal-title":"Cephalalgia"},{"issue":"13","key":"7496_CR28","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e1377","journal-title":"Neurology"},{"issue":"22","key":"7496_CR29","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122","journal-title":"N Engl J Med"},{"issue":"9","key":"7496_CR30","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"8","key":"7496_CR31","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442\u20131454","journal-title":"Cephalalgia"},{"issue":"24","key":"7496_CR32","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2221","journal-title":"Neurology"},{"issue":"4","key":"7496_CR33","doi-asserted-by":"crossref","first-page":"333102423115692","DOI":"10.1177\/03331024231156922","volume":"43","author":"S Giri","year":"2023","unstructured":"Giri S, Tronvik E, Linde M, Pedersen SA, Hagen K (2023) Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: a systematic review and meta-analysis. Cephalalgia 43(4):3331024231156922","journal-title":"Cephalalgia"},{"issue":"1","key":"7496_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"I Frattale","year":"2021","unstructured":"Frattale I, Caponnetto V, Casalena A, Assetta M, Maddestra M, Marzoli F et al (2021) Association between response to triptans and response to erenumab: real-life data. J Headache Pain 22(1):1","journal-title":"J Headache Pain"},{"issue":"1","key":"7496_CR35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s10194-023-01552-x","volume":"24","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, Fitzek M, Overeem LH, Storch E, Terhart M, Reuter U (2023) Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain. 24(1):16","journal-title":"J Headache Pain."},{"issue":"7","key":"7496_CR36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1526-4610.1994.hed3407394.x","volume":"34","author":"PJ Goadsby","year":"1994","unstructured":"Goadsby PJ, Edvinsson L (1994) Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 34(7):394\u20139","journal-title":"Headache"},{"issue":"1","key":"7496_CR37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s10194-017-0811-5","volume":"18","author":"S Benemei","year":"2017","unstructured":"Benemei S, Cortese F, Labastida-Ram\u00edrez A, Marchese F, Pellesi L, Romoli M et al (2017) Triptans and CGRP blockade - impact on the cranial vasculature. J Headache Pain 18(1):103","journal-title":"J Headache Pain"},{"issue":"6","key":"7496_CR38","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14(6):338\u2013350","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"7496_CR39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33(1):48\u201356","journal-title":"Ann Neurol"},{"issue":"Pt 3","key":"7496_CR40","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/brain\/117.3.427","volume":"117","author":"PJ Goadsby","year":"1994","unstructured":"Goadsby PJ, Edvinsson L (1994) Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 117(Pt 3):427\u201334","journal-title":"Brain"},{"issue":"3","key":"7496_CR41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1468-2982.2005.01016.x","volume":"26","author":"P Sarchielli","year":"2006","unstructured":"Sarchielli P, Pini LA, Zanchin G, Alberti A, Maggioni F, Rossi C et al (2006) Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia 26(3):257\u2013265","journal-title":"Cephalalgia"},{"key":"7496_CR42","doi-asserted-by":"crossref","first-page":"9547056","DOI":"10.1155\/2017\/9547056","volume":"2017","author":"V Vellani","year":"2017","unstructured":"Vellani V, Moschetti G, Franchi S, Giacomoni C, Sacerdote P, Amodeo G (2017) Effects of NSAIDs on the release of calcitonin gene-related peptide and prostaglandin E(2) from rat trigeminal ganglia. Mediators Inflamm 2017:9547056","journal-title":"Mediators Inflamm"},{"key":"7496_CR43","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.2147\/JPR.S322292","volume":"14","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Munjal S, Tepper SJ, Iaconangelo C, Serrano D (2021) A multicenter, randomized, double-blind, placebo-controlled study of the efficacy, tolerability, and safety of celecoxib oral solution (ELYXYB) in acute treatment of episodic migraine with or without aura. J Pain Res 14:2529\u20132542","journal-title":"J Pain Res"},{"issue":"1","key":"7496_CR44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1468-2982.1985.0501005.x","volume":"5","author":"ES Johnson","year":"1985","unstructured":"Johnson ES, Ratcliffe DM, Wilkinson M (1985) Naproxen sodium in the treatment of migraine. Cephalalgia 5(1):5\u201310","journal-title":"Cephalalgia"},{"issue":"11","key":"7496_CR45","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.58.11.1660","volume":"58","author":"M Dib","year":"2002","unstructured":"Dib M, Massiou H, Weber M, Henry P, Garcia-Acosta S, Bousser MG (2002) Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology 58(11):1660\u20131665","journal-title":"Neurology"},{"issue":"Suppl 1","key":"7496_CR46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2165\/00003495-199300461-00031","volume":"46","author":"M Giacovazzo","year":"1993","unstructured":"Giacovazzo M, Gallo MF, Guidi V, Rico R, Scaricabarozzi I (1993) Nimesulide in the treatment of menstrual migraine. Drugs 46(Suppl 1):140\u2013141","journal-title":"Drugs"},{"issue":"3","key":"7496_CR47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jemt.1081","volume":"53","author":"DJ Williamson","year":"2001","unstructured":"Williamson DJ, Hargreaves RJ (2001) Neurogenic inflammation in the context of migraine. Microsc Res Tech 53(3):167\u2013178","journal-title":"Microsc Res Tech"},{"issue":"1","key":"7496_CR48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neulet.2009.01.032","volume":"452","author":"XC Zhang","year":"2009","unstructured":"Zhang XC, Kainz V, Jakubowski M, Burstein R, Strassman A, Levy D (2009) Localization of COX-1 and COX-2 in the intracranial dura mater of the rat. Neurosci Lett 452(1):33\u201336","journal-title":"Neurosci Lett"},{"issue":"1","key":"7496_CR49","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/head.12224","volume":"54","author":"A Srikiatkhachorn","year":"2014","unstructured":"Srikiatkhachorn A, le Grand SM, Supornsilpchai W, Storer RJ (2014) Pathophysiology of medication overuse headache\u2013an update. Headache 54(1):204\u2013210","journal-title":"Headache"},{"issue":"1","key":"7496_CR50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/jpet.106.106971","volume":"320","author":"S Akerman","year":"2007","unstructured":"Akerman S, Holland PR, Goadsby PJ (2007) Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther 320(1):64\u201371","journal-title":"J Pharmacol Exp Ther"},{"issue":"5941","key":"7496_CR51","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1126\/science.1171870","volume":"325","author":"AJ Pern\u00eda-Andrade","year":"2009","unstructured":"Pern\u00eda-Andrade AJ, Kato A, Witschi R, Nyilas R, Katona I, Freund TF et al (2009) Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science 325(5941):760\u2013764","journal-title":"Science"},{"issue":"4","key":"7496_CR52","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/ejn.14897","volume":"55","author":"E Kilinc","year":"2022","unstructured":"Kilinc E, Ankarali S, Torun IE, Dagistan Y (2022) Receptor mechanisms mediating the anti-neuroinflammatory effects of endocannabinoid system modulation in a rat model of migraine. Eur J Neurosci 55(4):1015\u20131031","journal-title":"Eur J Neurosci"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07496-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07496-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07496-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T10:31:13Z","timestamp":1723026673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07496-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["7496"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07496-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study is a systematic review and meta-analysis, and thus does not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval\u00a0and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}